

DRUG PRIOR AUTHORIZATION COMMITTEE

December 19, 2019

Agenda

MO Coalition for Community Behavioral Healthcare
Lower Level CEO Room,
221 Metro Drive, Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 - 10:10	Minutes Review	Discussion/Approval
10:10 - 10:20	Pharmacy Program/ Budget Update	Elizabeth Short
10:20 - 10:25	DUR Update	Josh Moore

Old Business

10:25 – 10:35	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Josh Moore/ Mark Roaseau
---------------	--	-----------------------------

New Business

10:35 – 11:00	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization	Josh Moore/ Mark Roaseau
---------------	---	-----------------------------

11:00 – 11:45	<u>C. Clinical and Fiscal Edits</u> <p>Discussion, Public Hearing and Decision will be held for each edit</p> <ul style="list-style-type: none">I. 15 Day Supply – Oral Oncology Fiscal EditII. 15 Day Supply Fiscal EditIII. Acetaminophen Cumulative Dose Clinical EditIV. Biosimilar Fiscal EditV. Corlanor Clinical EditVI. Cystic Fibrosis Clinical EditVII. Diabetic Supply Quantity Limit Fiscal EditVIII. Entresto Clinical EditIX. High Cost Medication Kits Fiscal EditX. MME Accumulation Clinical EditXI. Non-Oral Contraceptive Clinical Fiscal EditXII. PrEP Fiscal EditXIII. Short-Acting Opioid Combinations Clinical EditXIV. Short-Acting Opioid Single Agents Clinical EditXV. TIRF Clinical EditXVI. Typical Antipsychotic Clinical EditXVII. Zolresso Clinical Edit	
---------------	--	--

11:45 – 12:45 **D. Preferred Drug List (PDL)**

Discussion, Public Hearing and Decision will be held for each edit

- I. Alzheimer’s Agents**
- II. Antiandrogenic Agents PDL Edit**
- III. Antiemetic Agents: 5-HT3, NK1 & Other Agents**
- IV. Antiemetic Agents: THC Derivatives**
- V. Anti-Migraine Agents: Serotonin (5-HT1) Receptor Agonists**
- VI. Anti-Parkinsonism: MAO-B Inhibitor Agents**
- VII. Anti-Parkinsonism: Non-Ergot Dopamine Agonists**
- VIII. Calcitonin Gene-Related Peptide (CGRP) Inhibitors**
- IX. Cox-II Inhibitor Agents**
- X. Fibromyalgia**
- XI. GI Motility Agents**
- XII. Glucagon Products**
- XIII. Hereditary Angioedema Agents**
- XIV. Long-Acting Opioid Agents**
- XV. Neuropathic Pain Agents**
- XVI. NSAIDs**
- XVII. Opiate Dependence Agents**
- XVIII. Opiate Emergency Reversal Agents**
- XIX. Respiratory Monoclonal Antibodies (RMA)**
- XX. Sedative Hypnotic Agents**
- XXI. Skeletal Muscle Relaxants**
- XXII. Tramadol-Like Agents**

11:45 – 12:45 **E. Reference Drug List**

Discussion, Public Hearing and Decision will be held for each edit

- I. Atypical Antipsychotics – Reference List**
- II. Antiretrovirals, Treatment– Reference List**

F. Preferred Drug List Classes for Dec/Jan

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information - Conduent Update

Olivia Rush

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: March 19, 2020

MO Coalition for Community Behavioral Healthcare
Lower Level CEO Room,
221 Metro Drive, Jefferson City, MO